STOCK TITAN

Retension Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Corporate Update

(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags

Retension Pharmaceuticals (RTSN) reported third-quarter results and detailed its October initial public offering, which raised $51.75 million in gross proceeds. The company sold 4,312,500 common shares at $12.00 each and received approximately $45.1 million in net proceeds.

Third-quarter net loss widened to $5.9 million from $1.5 million a year earlier as clinical trial and personnel costs rose. Cash and cash equivalents fell to $9.2 million at September 30, 2026, from $18.9 million at December 31, 2025. Including the post-quarter offering proceeds, September 30 cash and cash equivalents would have been approximately $54.3 million.

The company said the proceeds will fund completion of the ongoing Phase 2b trial of RTN-001 for uncontrolled hypertension and preparations for Phase 3. Initial Phase 2b results are expected in the first half of 2027.

Loading...
Loading translation...
3 points · 1 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

1 major · 9 points

Hollow bars mark forward-looking points. How the balance works

Positive

  • Major pointCompleted October 2026 IPO raised $51.75 million gross and approximately $45.1 million net, bringing September 30 pro forma cash and cash equivalents to approximately $54.3 million. 54% of market cap
  • Minor point. Forward-looking: it has not happened yet and may not happen.IPO funding will cover completion of the RTN-001 Phase 2b trial and preparations for Phase 3, Retension said.
  • Minor point. Forward-looking: it has not happened yet and may not happen.RTN-001 Phase 2b trial is ongoing, with initial results expected in the first half of 2027 to help select doses for Phase 3.

Negative

  • Major pointIPO issuance of 4,312,500 common shares at $12.00 each diluted existing holders and included 562,500 shares from the fully exercised underwriters’ option.
  • Moderate pointNet loss widened year over year to $5,918,084 from $1,475,814 for the quarter and to $13,443,134 from $3,361,487 for the nine months ended September 30, 2026.
  • Moderate pointCash and cash equivalents fell to $9,190,083 at September 30, 2026, from $18,901,024 at December 31, 2025, before IPO proceeds.
  • Minor pointNet loss per share widened year over year to $7.33 from $1.83 for the quarter and to $16.65 from $4.17 for the nine months ended September 30, 2026.
  • Minor pointResearch and development expenses rose year over year to $5,016,602 from $1,365,256 for the quarter and to $11,219,240 from $2,542,254 for the nine months ended September 30, 2026.
4 minor points
  • Minor pointCurrent liabilities rose to $6,658,829 at September 30, 2026, from $912,166 at December 31, 2025.
  • Minor pointStockholders’ deficit widened to $20,664,102 at September 30, 2026, from $7,782,923 at December 31, 2025.
  • Minor pointGeneral and administrative expenses rose year over year to $990,759 from $299,574 for the quarter and to $2,574,495 from $1,231,791 for the nine months ended September 30, 2026.
  • Minor pointInterest income fell year over year to $89,277 from $189,016 for the quarter and to $351,457 from $412,558 for the nine months ended September 30, 2026.

Key Figures

IPO terms: 4,312,500 shares at $12.00 per share Gross IPO proceeds: $51.75 million Net IPO proceeds: approximately $45.1 million +5 more
IPO terms
4,312,500 shares at $12.00 per share
Completed in October 2026
Gross IPO proceeds
$51.75 million
Completed initial public offering
Net IPO proceeds
approximately $45.1 million
Completed initial public offering
Trial enrollment
approximately 280 patients
Ongoing Phase 2b trial of RTN-001
Topline data timing
first half of 2027
Expected for the Phase 2b trial
Cash and cash equivalents
$9.2 million
As of September 30, 2026; before IPO net proceeds
Pro forma cash and cash equivalents
approximately $54.3 million
As of September 30, 2026, including net IPO proceeds
Net loss
$5.9 million
Third quarter of 2026

Key Terms

placebo-controlled, dose-ranging, systolic blood pressure, PDE5 inhibitor
4 terms
placebo-controlled medical
"The randomized, placebo-controlled, dose-ranging trial is evaluating RTN-001"
"Placebo-controlled" describes a testing method where one group receives the actual treatment or intervention, while another group receives a harmless, inactive version called a placebo. This approach helps determine whether the real treatment has genuine effects beyond psychological expectations. For investors, understanding this ensures confidence that reported benefits are real and not influenced by bias or false perceptions.
dose-ranging medical
"The randomized, placebo-controlled, dose-ranging trial is evaluating RTN-001"
A dose-ranging study is a clinical trial that tests multiple amounts of a drug to find what dose works best and is safest, much like trying different spice levels in a recipe to get the right balance. For investors, results clarify whether a medicine is effective at practical doses, how likely it is to win regulatory approval, what side effects to expect, and how the treatment might be priced and used in the market.
systolic blood pressure medical
"change from baseline in office-seated systolic blood pressure at Week 4 versus placebo"
Systolic blood pressure is the top number in a blood pressure reading, measuring the pressure in your arteries when your heart beats and pumps blood. It indicates how forcefully the heart pushes blood through the body. For investors, it can symbolize the maximum stress or intensity in a system, helping to assess overall health risks or stability.
PDE5 inhibitor medical
"a cardiovascular-targeted, next-generation PDE5 inhibitor designed to directly enhance"
A PDE5 inhibitor is a drug that blocks the enzyme phosphodiesterase type 5 to relax blood vessels and increase blood flow, most often used for erectile dysfunction and some types of pulmonary hypertension. Investors watch PDE5 inhibitors because clinical trial results, regulatory approval, patent life and market demand determine sales potential — like whether a key ingredient in a recipe will make a product sell well or not.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
  • IPO completed in October 2026 to support the continued development of RTN-001 for uncontrolled and resistant hypertension, affecting ~30 million Americans
  • Upsized IPO generated $51.75 million in gross proceeds
  • Topline data for Phase 2b clinical trial expected in first half of 2027

FALLS CHURCH, Va., Nov. 18, 2026 (GLOBE NEWSWIRE) -- Retension Pharmaceuticals, Inc. (Nasdaq: RTSN) (“Retension” or the “Company”), a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases, today reported financial results for the third quarter ended September 30, 2026, and provided a corporate update.

“Completing our initial public offering was an important step for Retension, and it provides the capital to complete our Phase 2b clinical trial of RTN-001 and prepare for Phase 3,” said Eric Keller, Chief Executive Officer of Retension Pharmaceuticals. “This year we have also built a leadership team with deep experience advancing cardiovascular and metabolic therapies from clinical development through approval, and formed a Scientific Advisory Board of leading investigators in hypertension, cardiology and nephrology. We remain focused on executing the Phase 2b trial, with initial data expected in the first half of 2027, as we work to bring a new treatment option to patients with uncontrolled and resistant hypertension.”

Recent Corporate Highlights and Upcoming Milestones

Completed initial public offering: In October 2026, Retension completed its upsized initial public offering of 4,312,500 shares of common stock at $12.00 per share, which includes the full exercise of the underwriters’ option to purchase 562,500 additional shares. The offering generated gross proceeds of $51.75 million and net proceeds of approximately $45.1 million. Retension’s common stock began trading on the Nasdaq Capital Market under the ticker symbol “RTSN” on October 9, 2026.

Phase 2b clinical trial of RTN-001 ongoing: The randomized, placebo-controlled, dose-ranging trial is evaluating RTN-001 in approximately 280 patients with uncontrolled hypertension. The study's primary endpoint is the change from baseline in office-seated systolic blood pressure at Week 4 versus placebo. The trial will also inform dose selection for Phase 3. Topline data are expected in the first half of 2027.

Strengthened executive leadership team:

  • Alison D. Schecter, M.D., FACC, FCCP, Chief Medical Officer: Oversaw three hypertension registration trials at Mineralys Therapeutics
  • Alex Schwartz, Chief Financial Officer: Joined from Ventyx Biosciences, where he led financial planning and investor relations
  • LeAnne Bloedon, M.S., RD, Executive Vice President, Clinical Development and Operations: Former Head of Development at Esperion Therapeutics
  • Kevin Schutz, PharmD, Vice President, Regulatory Affairs: Joined from Corxel Pharmaceuticals, where he served as Vice President, Global Regulatory Affairs
  • Robert Wong, Vice President, Chief Accounting Officer: Joined from Save Mart, where he was Vice President of Accounting; previously Vice President, Chief Accounting Officer of Cytokinetics and Controller and Chief Accounting Officer of Genentech

Added biopharma and cardiovascular leadership to the Board of Directors:

  • Pavan Cheruvu, M.D., Director: Chief Executive Officer of Amanat Acquisition Corp.; former President and CEO of Bitterroot Bio and President, CEO, and Chief R&D Officer of Sio Gene Therapies; early member of the Roivant Sciences executive team

Formed Scientific Advisory Board. Bringing together leading investigators in hypertension, cardiology and nephrology:

  • Omar Al Dhaybi, M.D., MSc, FASN, Director, American Heart Association Comprehensive Hypertension Center, Mount Sinai Fuster Heart Hospital; Assistant Professor of Medicine, Icahn School of Medicine at Mount Sinai
  • James L. Januzzi, M.D., Adolph Hutter Professor of Medicine, Harvard Medical School; Massachusetts General Hospital; Chief Scientific Officer, Baim Institute for Clinical Research
  • Luke J. Laffin, M.D., Preventive Cardiology, Cleveland Clinic; Associate Professor of Medicine, Cleveland Clinic Lerner College of Medicine; Chair, Steering Committee for Retension’s Phase 2b trial
  • Ian Wilkinson, M.D., Professor of Therapeutics and Director, Cambridge Clinical Trials Unit, University of Cambridge; President, British and Irish Hypertension Society
  • Randall M. Zusman, M.D., Director, Division of Hypertension, Massachusetts General Hospital Heart Center; Associate Professor of Medicine, Harvard Medical School

Third Quarter 2026 Financial Results

  • Cash position: Cash and cash equivalents were $9.2 million as of September 30, 2026, compared to $18.9 million as of December 31, 2025. These amounts do not reflect the net proceeds of the IPO, which closed after quarter-end. Including net IPO proceeds of approximately $45.1 million, pro forma cash and cash equivalents as of September 30, 2026 were approximately $54.3 million.
  • Research and development expenses: Research and development expenses were $5.0 million for the third quarter of 2026, compared to $1.4 million for the third quarter of 2025. The increase was primarily due to Phase 2b clinical trial costs.
  • General and administrative expenses: General and administrative expenses were $1.0 million for the third quarter of 2026, compared to $0.3 million for the third quarter of 2025. The increase was primarily due to higher personnel costs.
  • Net loss: Net loss was $5.9 million for the third quarter of 2026, compared to a net loss of $1.5 million for the third quarter of 2025 due to additional R&D and G&A expenses.

About Retension Pharmaceuticals

Retension Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases. The Company’s lead clinical candidate, RTN-001, is in development for patients with uncontrolled and resistant hypertension.

About RTN-001

Retension Pharmaceuticals is developing RTN-001, a cardiovascular-targeted, next-generation PDE5 inhibitor designed to directly enhance nitric oxide signaling in central arteries not adequately reached by first-generation PDE5 inhibitors, thereby addressing a core driver of hypertension. RTN-001 has been studied in multiple clinical trials totaling 265 subjects. RTN-001 has a demonstrated efficacy and safety profile in patients and healthy volunteers with clinically meaningful reductions in blood pressure. A Phase 2b trial of RTN-001 in hypertension is ongoing. RTN-001 is being developed under an exclusive world-wide license from Sanofi S.A.

For more information, please see www.retensionpharmaceuticals.com.

Special Note Regarding Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact contained in this press release, including, but not limited to, statements regarding the Company’s expected cash runway, the use of proceeds from its initial public offering, and the design, progress, timing and results of its Phase 2b clinical trial of RTN-001, and other statements regarding Retension’s future results of operations or financial condition, business strategy and plans, and objectives of management for future operations, are forward-looking statements. These forward-looking statements are based on Retension’s current expectations and assumptions about future events, which are inherently subject to uncertainties, risks and changes in circumstances that are difficult to predict, therefore you should not place undue reliance on these forward-looking statements. The words, including but not limited to, “anticipate,” “believe,” “can,” “contemplate,” “continue,” “could,” “design,” “estimate,” “expect,” “intend,” “may,” “might,” “objective,” “plan,” “potential,” “predict,” “project,” “shall,” “should,” “target,” “will,” or “would,” or the negative of these words or other similar terms or expressions are intended to identify these forward-looking statements. Retension’s actual results may differ materially from those expressed in, or implied by, such forward-looking statements due to a number of factors, including but not limited to, risks, uncertainties, assumptions and other factors described in the Company’s final prospectus filed with the U.S. Securities and Exchange Commission (“SEC”) on October 9, 2026 and its Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, as well as other documents that may be filed by the Company from time to time with the SEC. Retension undertakes no obligation to update any forward-looking statements after the date of this press release or to conform such statements to actual results or revised expectations, except as required by law.

Contact:

Press and Investor Contact
Alex Schwartz
Chief Financial Officer
investors@retensionpharmaceuticals.com

RETENSION PHARMACEUTICALS, INC.
Condensed Consolidated Statements of Operations (Unaudited)
 
  For the Three Months Ended For the Nine Months Ended
  September 30, September 30,
  2026 2025 2026 2025
Operating Expenses        
Research & development $5,016,602  $1,365,256  $11,219,240  $2,542,254 
General and administrative  990,759   299,574   2,574,495   1,231,791 
Total Operating Expenses  6,007,361   1,664,830   13,793,735   3,774,045 
Loss from Operations  (6,007,361)  (1,664,830)  (13,793,735)  (3,774,045)
Other Income (Expense)            
Exchange loss  —   —   (856)  — 
Interest income  89,277   189,016   351,457   412,558 
Total Other Income  89,277   189,016   350,601   412,558 
Net Loss $(5,918,084) $(1,475,814) $(13,443,134) $(3,361,487)
Net loss per share – Basic and diluted $(7.33) $(1.83) $(16.65) $(4.17)
Weighted-average common shares outstanding -Basic and diluted  807,894   805,154   807,287   805,154 


Condensed Consolidated Balance Sheets
 
    December 31,
  September 30, 2026 2025
  (unaudited) (As Restated)
Assets    
Current Assets    
Cash and cash equivalents $9,190,083  $18,901,024 
Prepaid expenses and other current assets  2,470,521   2,346,077 
Deferred offering costs  2,487,892   198,060 
Total Current Assets  14,148,496   21,445,161 
Total Assets  14,148,496   21,445,161 
Liabilities, Preferred Stock and Stockholders’ Deficit      
Current Liabilities      
Accounts payable  3,886,011   775,859 
Accrued expenses  2,772,818   136,307 
Total Current Liabilities  6,658,829   912,166 
Total Liabilities  6,658,829   912,166 
Commitments and Contingencies      
Convertible Preferred Stock  28,153,769   28,315,918 
Stockholders’ Deficit      
Common stock  81   81 
Additional paid-in-capital  1,094,140   532,185 
Accumulated deficit  (21,758,323)  (8,315,189)
Total Stockholders’ Deficit  (20,664,102)  (7,782,923)
Total Liabilities, Preferred Stock and Stockholders’ Deficit $14,148,496  $21,445,161 



FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much did Retension Pharmaceuticals raise in its October 2026 IPO?

Retension Pharmaceuticals raised $51.75 million gross and approximately $45.1 million net. It sold 4,312,500 common shares at $12.00 per share, including 562,500 shares from the underwriters’ full exercise of their option.

When are Retension Pharmaceuticals’ RTN-001 Phase 2b results expected?

Retension Pharmaceuticals expects initial results from the RTN-001 Phase 2b trial in the first half of 2027. The trial will also inform dose selection for Phase 3.

What is Retension Pharmaceuticals measuring in the RTN-001 Phase 2b trial?

The trial’s main measure is the change from baseline in seated systolic blood pressure measured in the office at Week 4 versus placebo. The randomized trial evaluates different doses in approximately 280 patients with uncontrolled hypertension.

Keep reading